A sample of our Publications and Presentations:

Publications

1. Georg Hess, Martin Dreyling Lucie Oberic, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haem. http://doi.org/10.1111/bjh.18519, 2022

2. Stéphane de Botton, Joseph M. Brandwein,  Andrew H. We, et al.  Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.  Cancer Medicine. http://doi.org/10.1002/cam4.4182, 2021.

3. Hübel K, Ostermann H, Glaß B, et. al. Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-018-0228-z, 2018.
4. Mohty M, Azar N, Chabannon C, et al. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis. Bone Marrow Transplant. https://doi.org/10.1038/s41409-017-0033-0, 2017.
5. Cremaschi L, von Versen R, Benzing T, et al. Induction Therapy with Rabbit Antithymocyte Globulin versus Basilximab after Kidney Transplantation: A Health Economic Analysis from a German Perspective. Accepted for publication in Transplant International. June 1, 2017.
6. Dombret H, Thomas X, Chevallier P, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. Journal of Medical Economics. 2016. Also published online.
7. Reitan JF, Kudrik FJ, Fox K, et al.  The Burden of Blood Transfusion:  A Utilization and Ecomonic Analysis- A Pilot Study in Patients with Chemotherapy-Induced Anemia (CIA).  J Med Econ. 2013;16(5):1-6.
8. Reitan JF, van Breda A, Corey-Lisle PK, et al.  Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices.  Clin Drug Investig. 2013. DOI 10.1007/s40261-013-0078-9.
9. Reitan, JF, van Breda A, Shreay S, et al.  Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients With Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics.  Hosp Pharm. 2013;48:120-26.
10. Reitan J, Moleski R, van Breda A, et al.  Cost and Quality Implications of Opioid-Based Postsurgical Pain Control in Total Abdominal Hysterectomy: A Study of Cost Outliers and Opioid-Related Adverse Events.  Hosp Pharm. 2012;47:855-62.
11. Adamson RT, Lew I, Beyzarov E, et al.  Clinical and Economic Impact of Intra- and Postoperative Use of Opioids and Analgesic Devices.  Hosp Pharm. 2011;46(supp):s1-s20.
12. Griffith N, Allen C, Pultz A, Penza S.  The Impact of a Long-Acting Erythropoiesis Stimulating Protein on Patient Throughput in a Hospital-Based Ambulatory Oncology Clinic.  Hosp Pharm.  2008;43:388–395.
13. Beveridge, R., Rifkin, R., Moleski, R., et al. Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction. Pharmacotherapy. 2003;23(12 Part 2):101S-109S.
14. Ueno W.  Costs of Outpatient Red Blood Cell Transfusions.  Journal of Supportive Oncology. 2006:4:494-95.
15. Milkovich G, Moleski R, Reitan J, et al.  Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy.  Pharmacotherapy. 2000;20:1432-40.

Presentations

1. An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. San Antonio, Texas February 21-24, 2024.
2. Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: A Chart Review Study. 20th IMS Annual Meeting from 27-30 September 2023 in Athens Greece.
3. A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi). ASH 2022.
4. Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study. ASH 65th Annual Meeting, Atlanta, GA, December 2021.
5. Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab: A Multinational, Retrospective Chart Review Study. EBMT Virtual Meeting, March 2022
6. KTE-X19 versus Standard of Care for Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with Bruton Tyrosine Kinase Inhibitors: Real-World Evidence from Europe. EHA Virtual Meeting, March 2021.
7. A Retrospective Record Review of Mobilization Strategies with and without Plerixafor for Autologous Stem Cell Transplant in Patients with Multiple Myeloma. EBMT Virtual Meeting, March 2021.
8. Ivosidenib improves overall survival relative to standard therapies in relapsed or refractory mutant IDH1 AML: results from matched comparisons to historical controls. ASH 2020. Virtual Meeting, December 2020.
9. Clinical Outcomes of EBV+ PTLD Patients Following HCT Who Fail Rituximab: A Retrospective Chart Review Study from France. EBMT 2020. Virtual meeting, August 2020
10. Ivosidenib Improves Overall Survival Relative To Standard Therapies In Relapsed Or Refractory Mutant IDH1 AML: Results From Matched Comparisons To Historical Controls. EHA 2020. Virtual Meeting, June 2020.
11. Adverse Events And Clinical Burden Associated With Chemotherapy In Patients With Relapsed Or Refractory EBV+ PTLD Following SOT: A Retrospective Chart Review Study From Germany And France. EHA 2020. Virtual Meeting, June 2020.
12. Propensity Score Matching Analysis: Indirect Comparison of IDHIAcuteFA® (Enasidenib) Versus Standard of Care in Mutant-IDH2 Relapsed or Refractory Myeloid Leukemia. Annual Meeting of the European Hematology Association (EHA), Amsterdam, Netherlands, June 2019.
13. Treatment Patterns and Outcomes in Patients With IDH2-Mutated Relapsed or Refractory Acute Myeloid Leukemia: A French Medical Chart Review Analysis. EHA 2019. Amsterdam, Netherlands. June 15, 2019.
14. A Time-Motion Observational Study of Clinic Staff: Administration of Pegfilgrastim Primary Prophylaxis via Next-Day Manual Injection and On-body Injector. ISPOR 2018. Baltimore, MD, May 21, 2018.
15. Plerixafor in Poor Mobilizers with Non-Hodgkin’s Lymphoma:  Multi-Center Time-Motion Analysis.  Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Marseille, France, March 2017.
16. Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) vs Basilximab after Kidney Transplantation: A Health Economic Analysis from a German Perspective. 2016 British Transplant Society Annual Meeting, February 24, 2016, Glasgow, Scotland.
17. Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) vs Basilximab after Kidney Transplantation: A Health Economic Analysis from a German Perspective. 2016 American Transplant Congress (ATC), June 13, 2016, Boston Massachusetts.
18. Time and Cost of Hospitalisations for Salvage Therapy Among Adult Patients With Philadelphia (Ph)-Negative B-Cell Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in Spain. ISPOR 19th Annual European Congress, Vienna, Austria, November 2, 2016.
19. Quantification of the Time and Effort Associated with Autologous Peripheral Blood Stem Cell Mobilization : A European Perspective. ASH 57th Annual Meeting and Exposition, Orlando, Florida, December 2015.
20. Hospitalisations Among Adult Patients With Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) Receiving Chemotherapy in Germany: A Retrospective Chart Review. ISPOR 18th Annual European Congress, Milan, Italy, November 2015.
21. Healthcare Burden and Economic Cost of Hospitalisation During Chemotherapy for Adult Patients With Ph-Negative B-Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in France: A Retrospective Chart Review.  ISPOR 18th Annual European Congress, Milan, Italy, November 2015.
22. Retrospective Chart Review of Hospitalisations During Chemotherapy for Adult Patients With Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in Italy.  ISPOR 18th Annual European Congress, Milan, Italy, November 2015.
23. Health Economic Analysis of Rabbit Antithymocyte Globulin (Thymoglobulin) Versus Basiliximab in Renal Transplantation – a German Perspective at the American Society Nephrology (ASN) Kidney Week, 2015, San Diego, California, November 2015.
24. Quantification of the Time and Effort Required for Autologous Peripheral Blood Stem Cell Collection: A European Perspective at the Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology (DGHO), Basel, Germany, October 2015.
25. Health Economic Analysis of Rabbit Antithymocyte Globulin (Thymoglobulin) Versus Basiliximab in Renal Transplantation – a German Perspective at the German Transplantation Society (DGT) 24th Annual Meeting, Dresden, Germany, October 2015.
26. Quantification of the Time and Effort Required for Autologous Peripheral Blood Stem Cell Collection: A European Perspective. Annual meeting of the European Hematology Association (EHA), Milan, Italy, June 2014.
27. Quantification of the Time and Efforts Required for Autologous Peripheral Blood Stem Cell Collection: A European Perspective. Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Milan, Italy, April 2014.
28. Utilization Patterns of Erythropoiesis Stimulating Agents Prescribed for Chemotherapy-Induced Anemia, and the Impact of the Outpatient Regimen on Subsequent Inpatient Use: A Pilot Study.  ASHP Midyear, December 2010.
29. Impact of Long- versus Short Acting Growth Factors on Staff Time Consumption and Utilization: A Multi-Center Study.  ASHP Annual Meeting, June 2006.
30. Impact of a Long-Acting Erythropoietic Growth Factor on Practice Dynamics in an Oncology Clinic.  ASHP Midyear, December 2006.
31. Time Burden of Blood Transfusion.  ASH, December 2005.